OpGen Inc. (NASDAQ: OPGN) raised $10.4 million in a recent funding round led by the Merck Global Health Innovation Fund, the venture capital arm of pharmaceutical giant Merck & Co.
The Gaithersburg biotech combats infectious disease, including so-called superbugs, with its molecular diagnostics and bioinformatics tools. The raise will support sales and marketing, as well as ongoing research and development, of the company's multidrug resistant organism platform called Acuitas Lighthouse.
In a Securities…
OpGen Inc. (NASDAQ: OPGN) raised $10.4 million in a recent funding round led by the Merck Global Health Innovation Fund, the venture capital arm of pharmaceutical giant Merck & Co.
The Gaithersburg biotech combats infectious disease, including so-called superbugs, with its molecular diagnostics and bioinformatics tools. The raise will support sales and marketing, as well as ongoing research and development, of the company's multidrug resistant organism platform called Acuitas Lighthouse.
In a Securities…